Overview

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow or in peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving clofarabine and cytarabine together with G-CSF may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine and to see how well it works when given together with cytarabine and G-CSF in treating patients with myelodysplastic syndromes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Nebraska
Collaborator:
National Cancer Institute (NCI)
Treatments:
Clofarabine
Cytarabine